Navigation Links
Gilead's AIDS Drug Awaits Patent in India

American bio-pharmaceutical major Gilead, which has entered into generic licensing deals with 10 Indian pharma firms to distribute its HIV drug Viread, is hoping to get a patent in India soon.

"We have made considerable progress in implementing our access programme and licensed Indian pharmas to manufacture Viread which originally announced a pricing of $1 a day for the pill," Gregg Alton, senior vice president and general counsel, Gilead Sciences, told IANS.

"After much discussion, Gilead now believes that a larger number of manufacturers will intensify competition and drive down prices even further," said Alton whose team was in Delhi last week.

Now, Gilead's application for a patent is pending before the Indian Patent office as it believes that it has a right to protect its intellectual property.

Indian pharma major Cipla has filed a pre-grant opposition against the patent application for Viread before the patents office.

But Alton said: "We believe that protecting the intellectual property of companies who engage in drug research and development is a critical part of the treatment access equation. Intellectual property protection, when used responsibly, encourages research and discovery of newer and more effective molecules.

"Gilead respects Cipla's right to oppose the issuance of a patent for Viread or any drug. But more importantly, we reaffirm our desire to work with Cipla whether or not a patent is issued," said Alton.

Gilead has signed generic licensing deals with 10 Indian pharma majors to distribute Viread in India and 94 other resource-limited countries.

More than 5.1 million people are believed to be infected with HIV in India - the second highest incidence of the disease after South Africa.

According to Alton, Viread (tenofovir disoproxil fumarate) is on its way to becoming the frontrunner drug across Europe for HIV/AIDS due to its low toxicity and resistance levels observed in patients.

The tablet-a-day dosage of the drug also helps in better regimen and compliance among the HIV/AIDS patients taking it.

Alton also pointed out that he expects generic versions of Gilead's anti-retrovirals to be available from several of its partners within the next few months.

When asked whether the drug would become unaffordable if Gilead was granted a patent for Viread in India, Alton assuaged fears voiced by critics and NGOs.

"The company plans to use this patent responsibly and has made its intention clear in the act of issuing non-exclusive voluntary licenses to Indian companies," he said.

"We have also planned a direct contact programme with NGOs and this open mode of communication will enable NGOs and Gilead to work on a common platform and fight the epidemic of AIDS together."

Currently, Gilead has signed agreements with Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Emcure Pharmaceuticals, FDC Ltd., Hetero Drugs, Matrix Laboratories Ltd., Medchem International, Ranbaxy Laboratories Ltd., Shasun Chemicals & Drugs Ltd and Strides Arcolab Ltd.


Related medicine news :

1. Vaccine For Cervical Cancer Awaits Approval
2. India Awaits Test Results To Confirm The Bird Flu Virus In Humans
3. Three-year-old AIDS Patient Awaits Death
4. Pfizer Awaits FDA Approval for New AIDS Drug, Maraviroc
5. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
6. HIV Patients Opposes Patenting Of AIDS Drug
7. Provigil Patent Extension Accorded To Cephalon
8. AIDS Sufferers Protest against Proposed Patent for Tenofovir
9. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
10. Venus Remedies Files 5th International Patent Application
11. US Court Rules Against Lupin in Ramipril Patent Case
Post Your Comments:

(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
Breaking Medicine Technology: